Patent SG-11201806134S-A (SG)
Title: Oncolytic viral vectors and uses thereof
Inventor: GREENBERG KENNETH P
IPC: C12N7/00
Filed: 2017-01-27
Abstract: 4 U 3000 Mock ONCR-003 ONCR-011 2000 0 0. LI 1000 u- 0 ▪ Mock • ONCR-003 ONCR-011 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/132552 Al 3 August 2017 (03.08.2017) WIPO I PCT (51) International Patent Classification: C12N 7/00 (2006.01) (21) International Application Number: PCT/US2017/015417 (22) International Filing Date: 27 January 2017 (27.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/287,619 27 January 2016 (27.01.2016) US (71) Applicant: ONCORUS, INC. [US/US]; 450 Kendall Street, 4th Floor, Cambridge, Massachusetts 02142 (US). (72) Inventors: GREENBERG, Kenneth P.; c/o Oncorus, Inc., 450 Kendall Street, 4th Floor, Cambridge, Massachu- setts 02142 (US). FINER, Mitchell H.; c/o Oncorus, Inc., 450 Kendall Street, 4th Floor, Cambridge, Massachusetts 02142 (US). (74) Agents: PHELAN, Jordan D. et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, Dis- trict of Columbia 20004-2400 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ONCOLYTIC VIRAL VECTORS AND USES THEREOF FIG. 33 11111111111111 0 111011111111111 010 11111 01110111 0111 OIEH11111 0111111111 0111111 Vector ICP4 miRNA site ICP27 miRNA site ONCR-003 miR-124 None ONCR-011 miR-124 miR-12 5 Post - mitotic Lung Cells miR 125a miR 124 PM-Lung >3000 <100 H 8, N CA <100 <100 A253 H & N Cancer cells W O 20 17 / 13 255 2 Al 600 2 TD 400 0 0 - 200 0. LL 0 17.‘ 1±\ b' 0 0 0 (57) : The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. 4 1 %